<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/22/voyager-therapeutics-inc-nasdaqvygr-receives-average-recommendation-of-hold-from-analysts.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-22T22:10:41+00:00"/>
    <meta property="og:title" content="Voyager Therapeutics Inc (NASDAQ:VYGR) Receives Average Recommendation of “Hold” from Analysts"/>
    <meta property="og:description" content="Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been given an average recommendation of “Hold” by the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average […]"/>
  </head>
  <body>
    <article>
      <h1>Voyager Therapeutics Inc (NASDAQ:VYGR) Receives Average Recommendation of “Hold” from Analysts</h1>
      <address><time datetime="2019-11-22T22:10:41+00:00">22 Nov 2019, 22:10</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/voyager-therapeutics-inc-logo.jpg"/>
      </figure>
      <p>Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been given an average recommendation of “Hold” by the eleven analysts that are currently covering the stock, <a href="https://www.marketbeat.com/">MarketBeat Ratings</a> reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $27.80.</p>
      <p>VYGR has been the subject of several analyst reports. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, November 6th. Morgan Stanley decreased their target price on shares of Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, October 11th. Nomura reissued a “buy” rating and issued a $37.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. BidaskClub cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research report on Monday, August 12th.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/VYGR/price-target/">NASDAQ:VYGR</a> traded down $0.06 during midday trading on Friday, hitting $14.26. The stock had a trading volume of 224,300 shares, compared to its average volume of 446,605. Voyager Therapeutics has a 12 month low of $7.76 and a 12 month high of $28.79. The business’s 50-day simple moving average is $14.99 and its 200-day simple moving average is $20.37. The company has a market cap of $501.79 million, a P/E ratio of -5.19 and a beta of 2.58.</p>
      <p>Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Wednesday, November 6th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.42. Voyager Therapeutics had a negative net margin of 72.64% and a negative return on equity of 57.32%. The business had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $3.94 million. On average, research analysts predict that Voyager Therapeutics will post -1.6 EPS for the current year.</p>
      <p>A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in shares of Voyager Therapeutics by 9.8% in the second quarter. BlackRock Inc. now owns 2,079,554 shares of the company’s stock valued at $56,605,000 after acquiring an additional 185,582 shares during the period. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 12.9% in the second quarter. Vanguard Group Inc. now owns 1,571,862 shares of the company’s stock valued at $42,787,000 after acquiring an additional 180,087 shares during the period. Renaissance Technologies LLC boosted its position in shares of Voyager Therapeutics by 48.2% in the second quarter. Renaissance Technologies LLC now owns 729,801 shares of the company’s stock valued at $19,865,000 after acquiring an additional 237,500 shares during the period. Invesco Ltd. boosted its position in shares of Voyager Therapeutics by 643.6% in the second quarter. Invesco Ltd. now owns 421,155 shares of the company’s stock valued at $11,464,000 after acquiring an additional 364,516 shares during the period. Finally, JPMorgan Chase &amp; Co. boosted its position in shares of Voyager Therapeutics by 28.0% in the second quarter. JPMorgan Chase &amp; Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after acquiring an additional 71,451 shares during the period. 78.20% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>
        <b>Voyager Therapeutics Company Profile</b>
      </p>
      <p>Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/what-is-a-swap/">Swap</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=VYGR"/>
      </figure>
    </article>
  </body>
</html>